Sort   by:  
 Page size 
KRAS-mutant colorectal cancer (KRASmut CRC) exhibits metabolic plasticity and chemoresistance, but the underlying mechanisms remain incompletely understood. Here, we show in CRC cells and organoids that KRAS-driven lactate accumulation promotes MCT1 K224 lactylation, which stabilizes mitochondrial M...
2026-10-16 | MTBLS16030 | MetaboLights
KRAS-mutant colorectal cancer (KRASmut CRC) exhibits metabolic plasticity and chemoresistance, but the underlying mechanisms remain incompletely understood. Here, we show in CRC cells and organoids that KRAS-driven lactate accumulation promotes MCT1 K224 lactylation, which stabilizes mitochondrial M...
2026-10-16 | MTBLS16034 | MetaboLights

KRAS-mutant colorectal cancer (KRASmut CRC) exhibits metabolic plasticity and chemoresistance, but the underlying mechanisms remain incompletely understood. Here, we show in CRC cells and organoids that KRAS-driven lactate accumulation promotes MCT1 K224 lactylation, which stabilizes mitochondria...

2026-10-16 | MTBLS16031 | MetaboLights

KRAS-mutant colorectal cancer (KRASmut CRC) exhibits metabolic plasticity and chemoresistance, but the underlying mechanisms remain incompletely understood. Here, we show in CRC cells and organoids that KRAS-driven lactate accumulation promotes MCT1 K224 lactylation, which stabilizes mitochondria...

2026-10-16 | MTBLS16037 | MetaboLights
Sort   by:  
 Page size